Что такое findslide.org?

FindSlide.org - это сайт презентаций, докладов, шаблонов в формате PowerPoint.


Для правообладателей

Обратная связь

Email: Нажмите что бы посмотреть 

Яндекс.Метрика

Презентация на тему Treatment options in oncology

Содержание

SurgeryRadiation therapyDrug therapy-anti-cancer drugs: - cytotoxic drugs - hormone therapy - cytokines, - targeted therapy: monoclonal antibodies & “small molecules”Drug that protect against side effects of chemotherapy
Treatment options in oncologySemenisty Valeriya, M.D27.09.2017 SurgeryRadiation therapyDrug therapy-anti-cancer drugs:  - cytotoxic drugs  - hormone therapy PalliativeIncreased survivalSymptom relief/Improved quality of lifeCurativeAdjuvant/Neoadjuvant (induction chemotherapy)Disease free survival (DFS) as Adjuvant:  -Breast cancer   -Colon cancer (Dukes` C2; Groups of cytotoxic drugs and mechanism of action Alkylating Agents & Platinum AnalogsAntimetabolitesTopoisomerase (I,II) interactive agentsAntimicrotubule AgentsMajor Groups of Cytotoxic Drugs The parent drug (prodrug) is activated to form an “active drug”, which DNA alkylation produces a variety of defects - double-and single-stranded Cyclophopsphamide (cytoxan)IfosfamideThe prodrug is activated by CYT-P-450 dependent metabolism in the liver.Chlorambucil (leukeran)Commonly used alkylating agents Nausea and vomiting are dose-related: > 90% for >1500 mg/m2, 60-90% for LeukopeniaNausea and/or vomitingAlopecia Hemorrhagic cystitis (1-10%)	Encephalopathy (10-50%)	Side Effects of Ifosfamide Cisplatin  -  Curative in testicular cancer and very active in Activation of Cisplatin in Aqueous Soloution This platinum-DNA adduct is repaired by the nucleotide excision repair (NER)  pathway ototoxicity (31%) 	myelosuppression 	nausea and vomiting (> 90%) 	neurotoxicity, usually peripheral neuropathies CarboplatinMyelosuppressionNausea and vomitingOxaliplatinneuropathy, sensory Myelosuppression	Side Effects AntimetabolitesAntimetabolites are antineoplastic agents that are structurally and chemically similar to naturally Antimetabolites & analogsMethotrexate……………..  Folic acid5-Fluorouracil……………  UracilCytosine arabinose……… DeoxycytosineGemcitabine……………...  DeoxycytosinePemetrexed Methotrexate - mechanism of actionMethotrexateDihydrofolate Reductase (DHFR)Binding & inhibitionFH2FH4 (reduced folates) Reduced Folates and Thymidylate synthetase (TS) 5 Fluorouracil (5FU)  5FU undergoes intracellular activation to the following active Cell cycle specific and non cell cycle specific drugsAlkylating agents and platinum Tubulin Binding AgentsVinca Alkaloids:Vincristine (Oncovin)Vinblastine Vinorelbine (Navelbine) Taxanes:Paclitaxel (Taxol)Docetaxel (Taxotere) Vinca AlkaloidsMechanism of action:  binding to specific site on tubulin with Mechanism of  action of taxanesBind to polymerized tubulin (beta subunit of Hormone therapy Hormone therapy in breast cancer: antiestrogens and aromatase inhibitors2/3 of all post-menopausal Target therapy Rituximab (Mabthera)  Rituximab is a genetically engineered chimeric murine/human monoclonal antibody Tyrosine kinase inhibitors TKIThe HER2 protein is a transmembrane thyrosine kinase that is a member Trastuzumab (Herceptin)A recombinant humanized monoclonal antibody that binds with the extracellular domain Epidermal growth factor receptor (EGFR) as a target EGFREGFR is a 170-kd transmembrane receptor. It has a tyrosine kinase activity.It EGFR inhibitorsMonoclonal antibodies: bind to the extracellular domain of the receptor. Example: Inhibitors of angiogenesis Avastin (Bevacizumab)VEGF (vascular endothelial growth factor) , a diffusible glycoprotein produced by Sunitinib (Sutent) –bind to intracellular domain VEGFR К наиболее распространенным побочным действиям циклофосфамида относятся все, кроме:1. миелосупрессия2. геморрагический цистит3. кардиальная токсичность4. энцефалопатияВопросы: Химиотерапевтическое лечение в онкологии применяется как:1.паллиация (симптоматическое лечение)2. куративное лечение (излечение)3. предоперационное лечение4. все верно Основной препарат, используемый в лечении рака яичек (Testicular Cancer):1. Паклитаксел (Таксол)2. Метотрексат3. Цисплатин4. Флюроурацил (5FU) К ингибиторам ароматазы относятся все перечисленные препараты, кроме:1.Тамоксифен2.Летрозол3.Фазлодекс4.1,35.Экзаместен Трастузумаб (Герцептин) это:1. анти HER-2 антитело2. антиметаболит3. блокатор тирозинкиназы4. анти VEGF антитело
Слайды презентации

Слайд 2 Surgery
Radiation therapy
Drug therapy-anti-cancer drugs:
- cytotoxic drugs

SurgeryRadiation therapyDrug therapy-anti-cancer drugs: - cytotoxic drugs - hormone therapy -

- hormone therapy
- cytokines,

- targeted therapy: monoclonal antibodies & “small molecules”

Drug that protect against side effects of chemotherapy

Anti-cancer treatment modalities


Слайд 3
Palliative
Increased survival
Symptom relief/Improved quality of life
Curative
Adjuvant/Neoadjuvant (induction chemotherapy)
Disease

PalliativeIncreased survivalSymptom relief/Improved quality of lifeCurativeAdjuvant/Neoadjuvant (induction chemotherapy)Disease free survival (DFS)

free survival (DFS) as end point in adjuvant chemotherapy
Goals

of cancer chemotherapy

Слайд 4 Adjuvant:
-Breast cancer

Adjuvant: -Breast cancer  -Colon cancer (Dukes` C2; i.e.

-Colon cancer (Dukes` C2; i.e.
positive regional

lymph nodes)
Neoadjuvant:
-Osteogenic sarcoma
- Gastric Adenocarcinoma


Adjuvant/neoadjuvant chemotherapy with proven efficacy


Слайд 5
Groups of cytotoxic drugs and
mechanism of action

Groups of cytotoxic drugs and mechanism of action

Слайд 6 Alkylating Agents & Platinum Analogs

Antimetabolites

Topoisomerase (I,II) interactive agents

Antimicrotubule

Alkylating Agents & Platinum AnalogsAntimetabolitesTopoisomerase (I,II) interactive agentsAntimicrotubule AgentsMajor Groups of Cytotoxic Drugs

Agents
Major Groups of Cytotoxic Drugs


Слайд 7 The parent drug (prodrug) is activated to form

The parent drug (prodrug) is activated to form an “active drug”,

an “active drug”, which has an alkylating group.

The “active

drug”, which is positively charged, binds covalentely to various macromolecules at nucleophylic sites.

The biological effect results mainly from alkylation of DNA bases (particularly the electron-rich N-7 position of guanine) and formation of DNA adducts.


Alkylating agents


Слайд 8 DNA alkylation produces a variety of

DNA alkylation produces a variety of defects - double-and single-stranded

defects - double-and single-stranded breaks

Bifunctional alkylating agent

form interstrand DNA crosslinking, which disrupt DNA replication and transcription.


Alkylating agents


Слайд 9
Cyclophopsphamide (cytoxan)
Ifosfamide
The prodrug is activated by CYT-P-450
dependent

Cyclophopsphamide (cytoxan)IfosfamideThe prodrug is activated by CYT-P-450 dependent metabolism in the liver.Chlorambucil (leukeran)Commonly used alkylating agents

metabolism in the liver.

Chlorambucil (leukeran)


Commonly used alkylating agents


Слайд 10 Nausea and vomiting are dose-related:
> 90% for

Nausea and vomiting are dose-related: > 90% for >1500 mg/m2, 60-90%

>1500 mg/m2,
60-90% for 750-1500 mg/m2,
30-60% for

750 mg/m2 or oral;

Myelosuppression

Hemorrhagic cystitis (up to 40%) with high-dose and/or long term therapy - severe, potentially fatal

Alopecia (40-60%);



Side Effects of Cyclophosphamide


Слайд 11 Leukopenia

Nausea and/or vomiting

Alopecia

Hemorrhagic cystitis (1-10%)

Encephalopathy (10-50%)



Side Effects

LeukopeniaNausea and/or vomitingAlopecia Hemorrhagic cystitis (1-10%)	Encephalopathy (10-50%)	Side Effects of Ifosfamide

of Ifosfamide


Слайд 12 Cisplatin -
Curative in testicular

Cisplatin -  Curative in testicular cancer and very active in

cancer and very active in ginecologic, GI, GU,

Head and neck, lung cancers

Carboplatin
Ovarian, lung cancer
the difference between the cisplatin and carboplatin molecules is in the leaving groups

Oxaliplatin
Colorectal cancer


Platinum analogs


Слайд 13
Activation of Cisplatin in Aqueous Soloution

Activation of Cisplatin in Aqueous Soloution

Слайд 15 This platinum-DNA adduct is repaired by the nucleotide

This platinum-DNA adduct is repaired by the nucleotide excision repair (NER) pathway

excision repair (NER)
pathway


Слайд 16 ototoxicity (31%)

myelosuppression

nausea and vomiting (> 90%)

ototoxicity (31%) 	myelosuppression 	nausea and vomiting (> 90%) 	neurotoxicity, usually peripheral



neurotoxicity, usually peripheral neuropathies

nephrotoxicity (28-36%)

Side Effects of

CDDP

Слайд 17 Carboplatin
Myelosuppression
Nausea and vomiting

Oxaliplatin
neuropathy, sensory
Myelosuppression


Side Effects

CarboplatinMyelosuppressionNausea and vomitingOxaliplatinneuropathy, sensory Myelosuppression	Side Effects

Слайд 18 Antimetabolites
Antimetabolites are antineoplastic agents that are structurally and

AntimetabolitesAntimetabolites are antineoplastic agents that are structurally and chemically similar to

chemically similar to naturally occurring compounds, required for synthesis

of purines, pyrimidines, and nucleic acids.

These drugs interfere with DNA synthesis by competitive inhibition of a key enzyme in the purine or pyrimidine synthesis pathway or by incorporation into the DNA or RNA molecules.









Слайд 19 Antimetabolites & analogs
Methotrexate…………….. Folic acid
5-Fluorouracil…………… Uracil
Cytosine

Antimetabolites & analogsMethotrexate…………….. Folic acid5-Fluorouracil…………… UracilCytosine arabinose……… DeoxycytosineGemcitabine……………... DeoxycytosinePemetrexed ……………… Pyrrolopyrimidine6-Mercaptopurine………. Hypoxantine6-Thioguanine…………… Guanine

arabinose……… Deoxycytosine
Gemcitabine……………... Deoxycytosine
Pemetrexed ……………… Pyrrolopyrimidine
6-Mercaptopurine………. Hypoxantine
6-Thioguanine……………

Guanine


Слайд 20 Methotrexate - mechanism of action
Methotrexate
Dihydrofolate Reductase (DHFR)
Binding &

Methotrexate - mechanism of actionMethotrexateDihydrofolate Reductase (DHFR)Binding & inhibitionFH2FH4 (reduced folates)

inhibition
FH2
FH4 (reduced folates)




Слайд 21 Reduced Folates and Thymidylate synthetase (TS)

Reduced Folates and Thymidylate synthetase (TS)

Слайд 22 5 Fluorouracil (5FU)
5FU undergoes intracellular activation

5 Fluorouracil (5FU) 5FU undergoes intracellular activation to the following active

to the following active nucleotides:
-fluorodeoxyuridine monophosphate (FdUMP):

This nucleotide inhibits Thymidylate synthetase (TS) and, therefore, inhibits DNA synthesis (competitive inhibition of a key enzyme).

-5-fluorouridine triphosphate (FUTP):
This nucleotide undergoes incorporation into RNA and, therefore, causes RNA damage.

Слайд 23
Cell cycle specific and non cell cycle specific

Cell cycle specific and non cell cycle specific drugsAlkylating agents and

drugs
Alkylating agents and platinum analogs are non cell cycle

specific

Antimetabolites are S-phase specific.

Слайд 24 Tubulin Binding Agents
Vinca Alkaloids:
Vincristine (Oncovin)
Vinblastine
Vinorelbine (Navelbine)


Taxanes:
Paclitaxel

Tubulin Binding AgentsVinca Alkaloids:Vincristine (Oncovin)Vinblastine Vinorelbine (Navelbine) Taxanes:Paclitaxel (Taxol)Docetaxel (Taxotere)

(Taxol)
Docetaxel (Taxotere)


Слайд 26 Vinca Alkaloids

Mechanism of action:
binding to specific

Vinca AlkaloidsMechanism of action: binding to specific site on tubulin with

site on tubulin with prevention of polymerization, inhibition of

microtubule assembly and mitotic spindle formation (leading to metaphase arrest)

Слайд 27 Mechanism of action of taxanes
Bind to polymerized tubulin

Mechanism of action of taxanesBind to polymerized tubulin (beta subunit of

(beta subunit of microtubules)

Binding is reversible and stabilize the

microtubules against depolymerization (induce tubular polymerization), thereby disrupting normal microtubule dynamics (halts mitosis) and lead to arrest at G2/M phase.


Слайд 28
Hormone therapy









Hormone therapy

Слайд 29
Hormone therapy in breast cancer: antiestrogens and aromatase

Hormone therapy in breast cancer: antiestrogens and aromatase inhibitors2/3 of all

inhibitors
2/3 of all post-menopausal breast cancers are hormone-sensitive, expressing

estrogen- and/or progesterone-receptors (ER/PgR)

Estrogens can stimulate cancer growth through binding to specific nuclear estrogen receptors (ER)

Cancer regression can be achieved by
Blocking estrogen receptors with an antiestrogen such as tamoxifen,faslodex
Effectively suppressing estrogen synthesis with aromatase inhibitors such as letrozole (femara) or anastrazole (arimidex) –through blocking conversion of androstenedione to estrone .
Non steroidal=Type II=reversible:
Anastrazole (Arimidex)
Letrozole (Femara)
Steroidal=Type I=irreversible:
Exemestane (Aromasin)

Слайд 30


Target therapy

Target therapy

Слайд 31
Rituximab (Mabthera)
Rituximab is a genetically engineered

Rituximab (Mabthera) Rituximab is a genetically engineered chimeric murine/human monoclonal antibody

chimeric murine/human monoclonal antibody directed against the CD20 antigen.

Active as single agent in CD-20 positive NHL and synergistic with chemotherapy in NHL.


Слайд 32

Tyrosine kinase inhibitors

Tyrosine kinase inhibitors

Слайд 33 TKI
The HER2 protein is a transmembrane thyrosine kinase

TKIThe HER2 protein is a transmembrane thyrosine kinase that is a

that is a member of the epidermal growth factor.

HER2

is a growth factor receptor.

HER2 is overexpressed in 20-30% of human breast cancers (in the majority, HER2 overexpression is caused by amplification of the HER2 gene).

Overexpression of HER 2 is associated with worse prognosis in breast cancer.


Слайд 34 Trastuzumab (Herceptin)
A recombinant humanized monoclonal antibody that binds

Trastuzumab (Herceptin)A recombinant humanized monoclonal antibody that binds with the extracellular

with the extracellular domain of the HER2 cell-surface receptor,

thereby inhibiting the growth of breast tumor cells that overexpress HER2.

It is active in breast cancer only in HER 2 positive pts, especially in combination with chemotherapy, both in metastatic disease and as adjuvant therapy in HER 2 positive tumors.



Слайд 35

Epidermal growth factor receptor (EGFR) as a target

Epidermal growth factor receptor (EGFR) as a target

Слайд 36 EGFR
EGFR is a 170-kd transmembrane receptor. It has

EGFREGFR is a 170-kd transmembrane receptor. It has a tyrosine kinase

a tyrosine kinase activity.

It has an extracellular ligand-binding domain,

a transmembrane segment and intracellular component.

When EGF (i.e. the ligand) binds to the extracellular domain, receptors dimers are formed with activation of the extracellular tyrosine kinase domain.
This results in autophosphorylation of downsream molecules with activation of multiple cellular functions including prpliferation and survival.

EGFR is often overexpressed (and is often mutated) in human tumors, thus there is a good rationale for trying to inhibit the EGFR.


Слайд 37 EGFR inhibitors
Monoclonal antibodies: bind to the extracellular domain

EGFR inhibitorsMonoclonal antibodies: bind to the extracellular domain of the receptor.

of the receptor. Example: Cetuximab (Erbitux),Panitumumab (vectibix).

Small molecules: bind

to the intracellular domain of the receptor.
example: Erlotinib (Tarceva).



Слайд 39

Inhibitors of angiogenesis

Inhibitors of angiogenesis

Слайд 40 Avastin (Bevacizumab)
VEGF (vascular endothelial growth factor) , a

Avastin (Bevacizumab)VEGF (vascular endothelial growth factor) , a diffusible glycoprotein produced

diffusible glycoprotein produced by normal and neoplastic cells ,has

been shown to have central role in the control of angiogenesis and to be essential for the development of tumor vasculature. VEGF (=ligand) binds to VEGF receptor.


Bevacizumab (Avastin) is a humanized anti- (VEGF) monoclonal antibody. It prevents VEGF to bond to its receptor, and therefore, has an antiangiogenic effect.




















Слайд 41
Sunitinib (Sutent) –bind to intracellular domain VEGFR

Sunitinib (Sutent) –bind to intracellular domain VEGFR

Слайд 42 К наиболее распространенным побочным действиям циклофосфамида относятся все,

К наиболее распространенным побочным действиям циклофосфамида относятся все, кроме:1. миелосупрессия2. геморрагический цистит3. кардиальная токсичность4. энцефалопатияВопросы:

кроме:

1. миелосупрессия
2. геморрагический цистит
3. кардиальная токсичность
4. энцефалопатия
Вопросы:


Слайд 43 Химиотерапевтическое лечение в онкологии применяется как:

1.паллиация (симптоматическое лечение)
2.

Химиотерапевтическое лечение в онкологии применяется как:1.паллиация (симптоматическое лечение)2. куративное лечение (излечение)3. предоперационное лечение4. все верно

куративное лечение (излечение)
3. предоперационное лечение
4. все верно


Слайд 44 Основной препарат, используемый в лечении рака яичек (Testicular

Основной препарат, используемый в лечении рака яичек (Testicular Cancer):1. Паклитаксел (Таксол)2. Метотрексат3. Цисплатин4. Флюроурацил (5FU)

Cancer):

1. Паклитаксел (Таксол)
2. Метотрексат
3. Цисплатин
4. Флюроурацил (5FU)


Слайд 45 К ингибиторам ароматазы относятся все перечисленные препараты, кроме:

1.Тамоксифен
2.Летрозол
3.Фазлодекс
4.1,3
5.Экзаместен

К ингибиторам ароматазы относятся все перечисленные препараты, кроме:1.Тамоксифен2.Летрозол3.Фазлодекс4.1,35.Экзаместен

  • Имя файла: treatment-options-in-oncology.pptx
  • Количество просмотров: 110
  • Количество скачиваний: 0